Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

200%(2 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_3

33%

Ph phase_4

33%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (33.3%)

Phase 41 (33.3%)

N/A1 (33.3%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatednot_applicable

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

NCT00745030

completedphase_3

Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)

NCT01048242

terminatedphase_4

Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease

NCT00462254

Clinical Trials (3)

Showing 3 of 3 trials

NCT00745030Not Applicable

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

Terminated

NCT01048242Phase 3

Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)

Completed

NCT00462254Phase 4

Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3